Wende Hutton

Big Pharma has a model to make a profit and save lives. So, whats the hold-up? - Blog - Business in Global Society - Harvard Business School hbs.edu/bigs/blog/post…

CEO @CliffordStocks and CMO Bob Lechleider enjoying their time in Chicago at the @ASCO annual meeting! #ASCO23 #EliteCancerResponders

@canaanpartners Looking ahead to helping the Antiva team bring a much-needed medicine to patients who suffer from hrHPV infections.

Antiva snags $53M Series E to advance ABI-2280 into efficacy studies for CIN 2,3 and high-risk #HPV infection. CEO Gail Maderis shifts to board chair; succeeded by Kristine Ball. Excited for next phase for company with potential to transform global health antivabio.com/news/2023/0427…

AACR 2023 has begun! OncoResponse has a poster presentation on April 19th, which will publicly introduce for the first time preclinical data regarding our dual-targeting antibodies for LILRB1 and LILRB2. The poster will soon be available on our website. #EliteCancerResponders

We are now two weeks away from presenting at #AACR2023! #OncoResponse's poster will publicly introduce for the first time our preclinical data of dual-targeting antibodies for LILRB1 and LILRB2. The poster presentation will take place April 19th. @AACR #EliteCancerResponders

Abyrx, Inc. announced additional FDA clearances for the company's MONTAGE® Settable, Resorbable Bone Putty as both a bone void filler and cranial bone cement, which follow the highly successful clinical introduction of MONTAGE use on bleeding bone. prnewswire.com/news-releases/…

Excited to see Qlaris Bio’s co-founder and CMO, Barbara Wirostko, on @endpts Women in Biopharma ’22 list. She is helping guide the co's effort to develop innovative therapies for debilitating ophthalmic diseases. Canaan's @WendeHutton is on co's BOD. endpts.com/special-report…

Big day for PACT Pharma. Data from 1st study using #CRISPR to substitute a gene in patient’s immune cells to treat cancer presented at #SITC2022 and published in @Nature. Groundbreaking research paves way for cutting-edge therapies. pactpharma.com/news/pact-phar…

Thrilled to see @HyalexOrtho appear on @BusinessInsider list of biotech startups to watch in next year. Excited to see what CEO @carl_vause and team accomplish. @WendeHutton @JuliePapanek @jesse_yeji Read full piece with BI subscription at: businessinsider.com/list-top-biote…

Exciting to see @OncoResponse's clinical supply agreement with @Regeneron to evaluate #OR2805 in combination with Libtayo. We'll be closely watching the clinical evaluation of this combination. Canaan's @WendeHutton is on the OncoResponse board. oncoresponse.com/news-center/pr…

IDEAYA announces positive interim data from P2 trial of darovasertib and crizotinib synthetic lethal combo. Provides rational for potential registration-enabling study in metastatic uveal melanoma. Canaan’s @TimShannonMD is chair of the IDEAYA board. media.ideayabio.com/2022-09-11-IDE…

Congrats to Julie and the Day One team! A new day for pediatric cancer patients: Day One's share price doubles on initial data for brain tumor drug fiercebiotech.com/biotech/new-da…

Lots of people talking about a string of negative data in biopharma… yes, there have been some notable upsets

Today, we welcome Alfonso "Chito" Zulueta to the #Glooko Board of Directors. Learn about his success at @LillyPad in the pharmaceutical industry and the experience he brings as we continue to grow as a #DigitalHealth leader: bit.ly/3Lruk24 #BetterTogether

Welcoming Chito Zulueto and his deep expertise in diabetes care to the Glooko board! glooko.com/news_reg/glook…

Glooko appoints Alfonso “Chito” Zulueta, former Eli Lilly & Company Senior Executive, to Board of Directors. glooko.com/news_reg/glook…

At #ATTD2022, #Glooko will showcase its #diabetes data management and #RemotePatientMonitoring platform and industry leaders will share insights on #DigitalHealth. Experience our #ConnectedCare platform at stand 24B: bit.ly/3KKgmYW #BetterTogether

Rondo Therapeutics has emerged from stealth mode with a bang. $67M Series A and ambitions to tackle solid tumors with next-gen #immunooncology platform. Round led by Canaan (@nkjellson) and Red Tree VC (Jon Edwards). PR from Rondo here: rondotx.com/news

Today, #Glooko announced the acquisition of DIABNEXT, a France-based company whose #DigitalHealth platform provides #diabetes #RemotePatientMonitoring and enhances physician-patient collaboration. Learn about Glooko XT, formerly DIABNEXT: bit.ly/3wfVPH4 #BetterTogether

Like @GlookoInc's own platform, the mobile app from acquisition target @DiabNext automatically takes in readings from continuous glucose monitors, insulin pumps and pens and other devices to help diabetes patients track daily health data. fiercebiotech.com/medtech/glooko…